RxDoctor Payments Data

Robert Pelberg, MD

Cardiovascular Disease · Montgomery, OHNPI 1326000530

Payments from drug & device makers

$108,388in general payments, 2019–2025

Across 27 payments — averaging $4014.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Elucid Bioimaging Inc$107K
  • Heartflow, Inc.$925
  • Atricure, Inc.$150
  • Amgen$18
  • Johnson & Johnson$13

What the payments were for

  • Consulting fees$107,31799%
  • Travel & lodging$5431%
  • Food & beverage$5290%

General payments by program year

19
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Elucid Bioimaging Inc16$107,281
Heartflow, Inc.7$925
Atricure, Inc.2$150
Amgen1$18
Johnson & Johnson1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$108,388 in reported general payments places this provider in the 90th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$206,153
Medicare patients
1,483
Services billed
3,145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban523$632,392
XareltoRivaroxaban246$299,857
Repatha SureclickEvolocumab219$238,924
EntrestoSacubitril/Valsartan170$224,369
JardianceEmpagliflozin85$127,794
VascepaIcosapent Ethyl73$69,316
FarxigaDapagliflozin Propanediol28$43,467
Praluent PenAlirocumab18$17,171
Repatha SyringeEvolocumab19$16,793
Ezetimibe499$12,631
Atorvastatin Calcium1,047$9,143
Metoprolol Succinate558$6,013
Rosuvastatin Calcium554$5,676
Ranolazine ErRanolazine39$5,484
Losartan Potassium628$4,642

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$13$299,857246 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Montgomery

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →